(Q35223205)

7 August 2017

1 reference

title

Superficial bladder cancer: diagnosis, surveillance and treatment (English)

1 reference

7 August 2017

Superficial bladder cancer: Diagnosis, surveillance and treatment (English)

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

29 November 2023

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

29 November 2023

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

29 November 2023

author name string

M. S. Soloway

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1305674

11 September 2022

P. E. Perito

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1305674

11 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1305674

11 September 2022

publication date

1 January 1992

1 reference

full work available at URL

7 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjcb.240501323

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

https://onlinelibrary.wiley.com/doi/full/10.1002/jcb.240501323

29 November 2023

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Journal of Cellular Biochemistry

29 November 2023

published in

1 reference

7 August 2017

volume

16I

1 reference

7 August 2017

page(s)

120-127

1 reference

Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resectio

7 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Exfoliative cytology after transurethral resection of superficial bladder tumours

29 November 2023

3

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Value of urine cytology versus bladder washing in bladder cancer

29 November 2023

4

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Outpatient flexible cystoscopy and fulguration of recurrent superficial bladder tumors

29 November 2023

5

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Initial evaluation and response criteria for patients with superficial bladder cancer. Report of a workshop

29 November 2023

6

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers

29 November 2023

7

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Rationalisation of follow-up in patients with non-invasive bladder tumours. A preliminary report.

29 November 2023

8

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms

29 November 2023

9

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Histopathological "self control" in transurethral resection of bladder tumours

29 November 2023

10

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Prostatic involvement in bladder cancer. Prostate mapping in 20 cystoprostatectomy specimens

29 November 2023

11

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Transitional cell carcinoma involving the prostate--an unfavourable prognostic sign in the management of bladder cancer?

29 November 2023

12

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis

29 November 2023

13

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer

29 November 2023

14

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer

29 November 2023

15

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial

29 November 2023

16

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer

29 November 2023

17

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

A continuous intravesical drug delivery system for the rat.

29 November 2023

18

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients

29 November 2023

19

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Intracavitary Chemotherapy of Diffuse Non-Infiltrating Papillary Carcinoma of the Bladder

29 November 2023

20

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa

29 November 2023

21

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C

29 November 2023

22

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

The effect of intravesical instillations of thiotepa, mitomycin C, and adriamycin on normal urothelium: an experimental study in rats

29 November 2023

23

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival

29 November 2023

24

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

The biology and treatment of superficial bladder cancer

29 November 2023

25

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Natural history and treatment of low and high risk superficial bladder tumors

29 November 2023

26

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma

29 November 2023

27

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder

29 November 2023

29

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers

29 November 2023

30

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin or adriamycin. Results of long-term follow-up

29 November 2023

32

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer

29 November 2023

33

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy

29 November 2023

34

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Toxic and therapeutic activity of 4'-epi-doxorubicin

29 November 2023

35

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Intravesical Instillations of 4-EPI-Doxorubicin (Epirubicin) in the Prophylactic Treatment of Superficial Bladder Cancer: Results of a Controlled Prospective Study

29 November 2023

36

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder

29 November 2023

37

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

29 November 2023

38

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

Intravesical interferon treatment of superficial bladder cancer

29 November 2023

39

1 reference

https://api.crossref.org/works/10.1002/JCB.240501323

29 November 2023

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1305674

11 September 2022

1 reference